TY - JOUR
T1 - Model structures of α-2 adrenoceptors in complex with automatically docked antagonist ligands raise the possibility of interactions dissimilar from agonist ligands
AU - Xhaard, Henri
AU - Nyrönen, Tommi
AU - Rantanen, Ville-Veikko
AU - Ruuskanen, Jori O.
AU - Laurila, Jonne
AU - Salminen, Tiina
AU - Scheinin, Mika
AU - Johnson, Mark S.
PY - 2005/5
Y1 - 2005/5
N2 - Antagonist binding to alpha-2 adrenoceptors (alpha2-ARs) is not well understood. Structural models were constructed for the three human alpha2-AR subtypes based on the bovine rhodopsin X-ray structure. Twelve antagonist ligands (including covalently binding phenoxybenzamine) were automatically docked to the models. A hallmark of agonist binding is the electrostatic interaction between a positive charge on the agonist and the negatively charged side chain of D3.32. For antagonist binding, ion-pair formation would require deviations of the models from the rhodopsin structural template, e.g., a rotation of TM3 to relocate D3.32 more centrally within the binding cavity, and/or creation of new space near TM2/TM7 such that antagonists would be shifted away from TM5. Thus, except for the quinazolines, antagonist ligands automatically docked to the model structures did not form ion-pairs with D3.32. This binding mode represents a valid alternative, whereby the positive charge on the antagonists is stabilized by cation-pi interactions with aromatic residues (e.g., F6.51) and antagonists interact with D3.32 via carboxylate-aromatic interactions. This binding mode is in good agreement with maps derived from a molecular interaction library that predicts favorable atomic contacts; similar interaction environments are seen for unrelated proteins in complex with ligands sharing similarities with the alpha2-AR antagonists.
AB - Antagonist binding to alpha-2 adrenoceptors (alpha2-ARs) is not well understood. Structural models were constructed for the three human alpha2-AR subtypes based on the bovine rhodopsin X-ray structure. Twelve antagonist ligands (including covalently binding phenoxybenzamine) were automatically docked to the models. A hallmark of agonist binding is the electrostatic interaction between a positive charge on the agonist and the negatively charged side chain of D3.32. For antagonist binding, ion-pair formation would require deviations of the models from the rhodopsin structural template, e.g., a rotation of TM3 to relocate D3.32 more centrally within the binding cavity, and/or creation of new space near TM2/TM7 such that antagonists would be shifted away from TM5. Thus, except for the quinazolines, antagonist ligands automatically docked to the model structures did not form ion-pairs with D3.32. This binding mode represents a valid alternative, whereby the positive charge on the antagonists is stabilized by cation-pi interactions with aromatic residues (e.g., F6.51) and antagonists interact with D3.32 via carboxylate-aromatic interactions. This binding mode is in good agreement with maps derived from a molecular interaction library that predicts favorable atomic contacts; similar interaction environments are seen for unrelated proteins in complex with ligands sharing similarities with the alpha2-AR antagonists.
KW - Adrenergic alpha-2 Receptor Agonists
KW - Adrenergic alpha-2 Receptor Antagonists
KW - Computer Simulation
KW - Humans
KW - Ligands
KW - Models, Molecular
KW - Phenoxybenzamine/chemistry
KW - Protein Binding
KW - Quinazolines/chemistry
KW - Receptors, Adrenergic, alpha-2/chemistry
KW - Rhodopsin/chemistry
KW - Static Electricity
KW - Structural Homology, Protein
KW - Yohimbine/chemistry
U2 - 10.1016/j.jsb.2004.12.008
DO - 10.1016/j.jsb.2004.12.008
M3 - Article
C2 - 15866736
SN - 1047-8477
VL - 150
SP - 126
EP - 143
JO - Journal of Structural Biology
JF - Journal of Structural Biology
IS - 2
ER -